Where Mounjaro comes from — and why it matters for your treatment

Eli Lilly: where Mounjaro was developed and why that matters

Eli Lilly has been making medicines since 1876. Mounjaro is one of its most significant recent developments, a dual GIP and GLP-1 receptor agonist that took years of clinical research before reaching patients. The compound, tirzepatide, was studied across Lilly's SURMOUNT clinical programme before regulators in the UK, US and elsewhere reviewed the data.

Knowing the manufacturer matters for a practical reason: if you are considering treatment through any UK pharmacy, the legitimate supply chain runs through Lilly's authorised UK distribution network. Pens sourced outside that chain (via social media sellers or sites that supply without a prescription) cannot be verified as genuine. The MHRA has warned repeatedly about counterfeit weight-loss pens entering the UK, including the first illicit UK manufacturing site producing fake tirzepatide pens, raided in Northampton in October 2025. Large seizures of fake pens have resulted in hospitalisations.

If you want to understand more about how tirzepatide's dual mechanism sets it apart from single-receptor medicines, our guide to what Mounjaro is made from covers the active ingredient and its formulation in detail.

Worth checking: any pharmacy dispensing Mounjaro in the UK should be verifiable on the GPhC pharmacy register. That is the fastest way to confirm you are dealing with a regulated, accountable service.

How Mounjaro moved from an American lab to UK pharmacies

Tirzepatide was originally developed for type 2 diabetes management and was studied extensively in Lilly's SURPASS programme. The SURMOUNT trials then investigated weight management specifically, with SURMOUNT-1 (involving 2,539 adults with obesity) reporting around 20 to 21 per cent average body-weight reduction at the 15mg dose over 72 weeks, published in the New England Journal of Medicine.

On the strength of that evidence, the MHRA granted a UK marketing authorisation for Mounjaro as a weight-management treatment in adults with a BMI of 30 or above, or 27 or above where a weight-related health condition is present. NICE then issued its recommendation (TA1026) in December 2024, covering NHS use in specific clinical cohorts. Private use via a regulated pharmacy operates under the same MHRA licence, but without the NHS eligibility thresholds, the prescriber assesses whether treatment is clinically appropriate for each individual.

For more on the manufacturing and supply side, where Mounjaro is made goes into the production process, including where Lilly manufactures its pens.

What the country of origin means for access and cost in the UK

Because Mounjaro is manufactured by a US company and priced in global markets, UK supply is subject to international pricing decisions. Eli Lilly raised its UK list price significantly from September 2025 (the highest dose's list price moved from around £122 to around £330 per four-week pen) and private market prices since then have typically ranged from roughly £149 to £375 per month depending on dose and provider, as widely reported at the time. Our breakdown of the Eli Lilly UK price increase explains what drove those changes and what they mean in practice.

The short version: where a medicine comes from (and which company controls its supply) can affect your costs as a patient. That is one reason the supply chain matters, not just the brand name on the pen.

At num, we source through the licensed UK supply chain and our clinical team reviews every consultation personally. If you would like to explore whether treatment is right for you, a good first step is reading about our weight-loss treatments and what the process involves.

Where to get Mounjaro, your real-world options

Once you understand that Mounjaro is a prescription-only medicine originating from Eli Lilly and regulated by the MHRA, the question shifts from where it comes from to how you actually access it. There are two main routes: NHS and private. NHS access is currently phased (the rollout began in June 2025 and cohort criteria have been broadening gradually) and getting Mounjaro from your GP depends on whether your practice is participating and whether you meet the current cohort criteria.

Private treatment through a regulated online pharmacy removes the waiting list and the cohort thresholds, subject to clinical suitability assessed by a prescriber. The full guide to accessing Mounjaro in the UK covers both routes side by side. And if you have already started treatment and have questions about technique, where to inject Mounjaro is a practical reference our prescribers point patients to regularly.

When you are ready to find out whether treatment is clinically appropriate for you, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not a queuing system.